2024-11-09 - Analysis Report
## AbbVie Inc (ABBV) Stock Analysis

**1. Performance Analysis:**

AbbVie Inc (ABBV) is a pharmaceutical company that develops, manufactures, and markets a range of prescription drugs. The company's stock has outperformed the S&P 500 (VOO) in the long run. 

**Cumulative Return:**

* **ABBV:** 159.87%
* **VOO:** 141.71%

**Divergence:**

* **Current Divergence:** 18.16%
* **Relative Divergence:** 59.51% (meaning ABBV's performance is currently at the 59.51% percentile of its historical performance relative to VOO)

**Alpha & Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|------|------|-----|-------|------|
| 2015-2017 | 46.8% | 30.2% | 16.6% | 1.0 |
| 2016-2018 | 60.0% | 34.1% | 35.3% | 1.0 |
| 2017-2019 | 41.9% | 43.6% | -1.2% | 1.0 |
| 2018-2020 | 8.9% | 43.6% | -30.2% | 0.8 |
| 2019-2021 | 51.7% | 33.7% | -38.1% | 0.7 |
| 2020-2022 | 80.5% | 33.7% | 62.7% | 0.6 |
| 2021-2023 | 47.0% | 22.4% | 18.2% | 0.4 |
| 2022-2024 | 48.1% | 22.4% | 23.4% | 0.3 |

* **CAGR:** ABBV consistently outperforms the market with high CAGR (Compound Annual Growth Rate).
* **MDD:** Maximum drawdown is relatively stable, indicating a relatively low-risk profile.
* **Alpha:** ABBV exhibits positive alpha in most periods, showcasing its ability to generate excess returns over the market.
* **Beta:** Beta is gradually decreasing, indicating a decreasing correlation to market fluctuations. 


**2. Recent Price Movement:**

* **Last Close:** 200.51
* **5-Day Moving Average:** 201.48
* **20-Day Moving Average:** 194.11
* **60-Day Moving Average:** 194.73

**3. Technical Indicators:**

* **RSI:** 68.64 (overbought territory)
* **PPO:** 0.59 (indicates strong bullish momentum)
* **Delta_Previous_Relative_Divergence:** -0.02 (short-term bearish signal, indicating a potential for a short-term pullback)
* **Expected Return:** 2.96% (estimated long-term outperformance over S&P 500)

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-10-30 | 3 | 2.92 |
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |

* **Recent Earnings:** ABBV consistently beats earnings expectations, demonstrating strong performance and profitability.
* **Outlook:**  Analysts are positive about ABBV's future prospects, expecting continued strong earnings growth.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue  | Profit Margin |
|---|---|---|
| 2024-09-30 | $14.46B | 70.87% |
| 2024-06-30 | $14.46B | 70.94% |
| 2024-03-31 | $12.31B  | 66.74% |
| 2023-12-31 | $14.30B  | 60.11% |
| 2023-09-30 | $13.93B  | 53.44% |

* **Revenue:**  ABBV has consistently generated strong revenue growth, showcasing its market dominance.
* **Profit Margin:** ABBV demonstrates impressive profitability with high profit margins, indicating efficient operations and strong pricing power.

**Capital and Profitability:**

| Quarter | Equity    | ROE |
|---|---|---|
| 2024-09-30 | $6.03B | 25.88% |
| 2024-06-30 | $6.78B | 20.21% |
| 2024-03-31 | $8.01B | 17.10% |
| 2023-12-31 | $10.36B  | 7.93% |
| 2023-09-30 | $12.09B | 14.70% |

* **Equity:**  ABBV has a solid financial foundation with strong equity levels.
* **ROE:** ROE (Return on Equity) is consistently strong, highlighting the company's ability to generate profits from its equity.

**6. News and Recent Issues:**

* **Recent Earnings News:**  Analyze recent earnings releases from reputable sources like **Shacknows** for specific insights on AbbVie's performance, guidance, and key developments discussed during the earnings calls.

* **Market Outlook:** Review recent market analysis from **FINBOLD** and other reliable financial news sources to understand the overall market sentiment and analyst opinions on ABBV's performance and future prospects.

* **Analyst Opinions and Performance Highlights:** Gather insights from analyst reports and research published by reputable financial institutions for a comprehensive view of ABBV's current performance, valuation, and potential growth drivers.

**7. Overall Analysis:**

ABBV is a strong, dividend-paying pharmaceutical company with a solid track record of growth and profitability. The stock has consistently outperformed the market and is showing strong momentum. However, it's important to acknowledge that it's currently in overbought territory based on RSI and might be due for a short-term pullback. Despite this, long-term investors might find ABBV's consistent earnings growth and strong financial position attractive. 

Before making any investment decisions, it's recommended to conduct thorough research and consider your own investment goals, risk tolerance, and financial situation. 

**Disclaimer:** This analysis is for informational purposes only and should not be considered as financial advice. 
